| Target | SaCas9 |
|---|
| Product Type | Antibody |
|---|
| Application | ICC, IP, WB |
|---|
| Clonality | Monoclonal |
|---|
| Conjugate | Unlabeled |
|---|
| Isotype | IgG2a ĸ |
|---|
| Immunogen | Recombinant protein, corresponding to amino acids 1-462 of Staphylococcus aureus Cas9 |
|---|
| Host Species | Mouse |
|---|
| Species Reactivity | Human, Mouse, Rat |
|---|
| Formulation | PBS containing 50% Glycerol (pH 7.2). No preservative is contained |
|---|
| Research Area | Apoptosis |
|---|
| Description/Background | The CRISPR/Cas9 system is an innovative tool for genome editing. In 2015, a new Cas9 gene was cloned from Staphylococcus aureus. The SaCas9 (Staphylococcus aureus Cas9) gene is 1 kb shorter than the SpCas9 (Streptococcus pyogenes Cas9) gene, which was originally used for genome editing (Ran FA, et al., 2015, Nature). The protospacer adjacent motif (PAM) sequence of SaCas9, required for DNA cleavage, is longer than that of SpCas9. These molecular characteristics of SaCas9 are expected to enable more efficient genome editing. |
|---|
| Storage Temperature | This antibody solution is stable for one year from the date of purchase when stored at -20°C. |
|---|
| Protocols | ICC, IP, WB |
|---|
| Clone Number | 11E7-9 |
|---|
| Concentration | 1 mg/mL |
|---|
| Source | Purified IgG from hybridoma supernatant |
|---|
| Regulatory Statement | For Research Use Only. Not for use in diagnostic procedures. |
|---|
